Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Novartis Pharmaceuticals is the lead sponsor of 248 current clinical trials in our USA, China, UK, India, Ireland and EU (CTIS) registers. 120 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Remibrutinib, Ianalumab and Iptacopan. The most-studied condition is Breast Cancer.

Company profiles on this site (news, sites, medicines, approvals): Novartis AG (CH) →Novartis Ireland (IE) →

ClinicalTrials.gov trials by status

Recruiting12052%
Active, closed11248%

Trials by phase

Phase 38034%
Phase 25925%
Phase 12913%
Observational2310%
Phase 1/2229%
Phase 4177%
Phase 2/321%

Clinical trials sponsored by Novartis Pharmaceuticals

232 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. NCT04817618 · C3G Drug: Iptacopan	Phase 3	Recruiting	2021-07	UK, USA, India, China
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN NCT05755386 · IC-MPGN Drug: Iptacopan	Phase 3	Recruiting	2023-10	UK, USA, India
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). NCT06133972 · Systemic Lupus Erythematosus Drug: Ianalumab	Phase 3	Recruiting	2024-05	USA, India, China
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) NCT04174157 · Spinal Muscular Atrophy (SMA) Drug: Zolgensma	Observational	Recruiting	2018-09	Ireland, USA, China
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V NCT05268289 · Lupus Nephritis Drug: Iptacopan	Phase 2	Recruiting	2022-08	UK, USA, India, China
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib NCT06401356 · Hematologic Malignancy, Solid Tumor, Advanced Malignancies Drug: Pelabresib	Phase 3	Recruiting	2024-08	UK, USA
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. NCT05939414 · Oligometastatic Prostate Cancer (OMPC) Drugs: AAA617, Piflufolastat	Phase 3	Recruiting	2024-03	UK, USA, China
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) NCT07517263 · Cardiovascular Disease and Lipoprotein(a) Drug: Pelacarsen	Phase 3	Recruiting	2026-05	UK, USA, India, China
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever NCT06006559 · Dengue	Phase 2	Recruiting	2024-02	India
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. NCT06846281 · Relapsing Multiple Sclerosis Drugs: Ocrelizumab, Remibrutinib	Phase 3	Recruiting	2025-06	UK, USA
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer NCT05827081 · ClinicalTrials.gov ↗ · Early Breast Cancer Drugs: Exemestane, Goserelin, Letrozole	Phase 3	Recruiting	2024-02	USA, India, China
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer Drugs: Fulvestrant, Letrozole	Phase 1/2	Recruiting	2025-12	USA
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) NCT06997588 · PIK3CA-related Overgrowth Spectrum (PROS) Drug: Alpelisib	Phase 2	Recruiting	2025-10	UK, USA
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes NCT07102628 · ClinicalTrials.gov ↗ · Acute Coronary Syndrome Drug: Inclisiran	Phase 3	Recruiting	2025-10	India, China
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment NCT07422610 · Advanced Malignancies and Hepatic Impairment Drug: Pelabresib	Phase 1	Recruiting	2026-05	UK
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease NCT06546670 · Sickle Cell Disease	Phase 1/2	Recruiting	2024-08	USA
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis NCT07225504 · ClinicalTrials.gov ↗ · Secondary Progressive Multiple Sclerosis (SPMS) Drug: Remibrutinib	Phase 3	Recruiting	2025-11	UK, USA, India, China
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN NCT06994845 · Primary Immunoglobulin A Nephropathy (IgAN) Drug: Iptacopan	Phase 3	Recruiting	2025-11	USA, China
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET NCT06784752 · Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Drug: Octreotide LAR	Phase 3	Recruiting	2025-05	UK, USA, China
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo NCT07431177 · ClinicalTrials.gov ↗ · Non-segmental Vitiligo Drug: GIA632	Phase 2	Recruiting	2026-03	USA, India, China
A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients NCT07635316 · Gastroenteropancreatic Neuroendocrine Tumor	Observational	Recruiting	2026-06	USA
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients NCT07408219 · Chronic Spontaneous Urticaria	Observational	Recruiting	2026-01	USA
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS NCT07665437 · Hidradenitis Suppurativa Drug: Remibrutinib	Phase 3	Recruiting	2026-07	USA
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease NCT07094516 · ClinicalTrials.gov ↗ · Alzheimer's Disease Drug: VHB937	Phase 2	Recruiting	2025-08	UK, USA, China
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies NCT05682378 · ClinicalTrials.gov ↗ · Heterozygous or Homozygous Familial Hypercholesterolemia Drug: Inclisiran	Phase 3	Recruiting	2023-02	UK, USA
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS NCT05795140 · ClinicalTrials.gov ↗ · Atypical Hemolytic Uremic Syndrome	Phase 3	Recruiting	2024-05	India, China
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) NCT07206056 · ClinicalTrials.gov ↗ · Progressive Metastatic Castrate Resistant Prostate Cancer Drug: JSB462	Phase 1/2	Recruiting	2025-10	UK, USA, China
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis NCT05646381 · ClinicalTrials.gov ↗ · Aortic Stenosis	Phase 2	Recruiting	2024-03	UK, USA
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study NCT06531499 · ClinicalTrials.gov ↗ · Metastatic Castration-Resistant Prostate Cancer Drug: AAA617	Phase 1	Recruiting	2024-11	UK, USA
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis NCT06744920 · ClinicalTrials.gov ↗ · Generalized Myasthenia Gravis Drug: Remibrutinib	Phase 3	Recruiting	2025-02	UK, USA, India, China
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas NCT04104776 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell Drugs: Enzalutamide, Tulmimetostat	Phase 1/2	Recruiting	2019-09	UK, USA
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727 · ClinicalTrials.gov ↗ · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) Drugs: Pelabresib, Ruxolitinib	Phase 3	Recruiting	2026-05	USA, India, China
Secukinumab Open Label Roll-over Extension Protocol NCT04638647 · ClinicalTrials.gov ↗ · Autoimmunity, Inflammation Drug: Secukinumab	Phase 4	Recruiting	2020-12	USA, India, China
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC NCT06855277 · ClinicalTrials.gov ↗ · Prostate Cancer Drugs: AAA817, ARPI	Phase 3	Recruiting	2025-07	UK, USA, India, China
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis NCT06470048 · ClinicalTrials.gov ↗ · Diffuse Cutaneous Systemic Sclerosis Drug: Ianalumab	Phase 2	Recruiting	2024-10	UK, USA, India, China
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent NCT04933552 · Multiple Sclerosis	Observational	Recruiting	2021-12	USA
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) NCT06711887 · Lupus Nephritis Drug: Ianalumab	Phase 3	Recruiting	2025-05	USA, China
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants NCT07783503 · ClinicalTrials.gov ↗ · Healthy Participants Drugs: Itraconazole, Pelabresib, Phenytoin	Phase 1	Recruiting	2026-09	UK
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) NCT05935215 · ClinicalTrials.gov ↗ · Atypical Hemolytic Uremic Syndrome Drug: Iptacopan	Phase 3	Recruiting	2024-02	UK, China
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) NCT07190300 · ClinicalTrials.gov ↗ · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Drugs: Abiraterone, Darolutamide, Tulmimetostat	Phase 1/2	Recruiting	2026-01	UK, USA, China
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors NCT05868629 · Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors	Observational	Recruiting	2024-02	USA
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN NCT07498335 · ClinicalTrials.gov ↗ · Berger Disease, Bergers Disease, IgA Nephropathy Drug: Atrasentan	Phase 3	Recruiting	2026-08	USA, China
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors NCT06726148 · ClinicalTrials.gov ↗ · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer Drugs: Fulvestrant, Ribociclib	Phase 1/2	Recruiting	2025-04	UK, USA, China
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia NCT04925479 · Myeloid Leukemia, Philadelphia Positive	Phase 1/2	Recruiting	2021-12	USA, China
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters. NCT07243002 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2025-12	UK
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration NCT07441642 · ClinicalTrials.gov ↗ · Geographic Atrophy Secondary to Age-related Macular Degeneration	Phase 2	Recruiting	2026-03	UK, USA
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) NCT07421167 · Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) Drugs: Avatrombopag, Eltrombopag, Ianalumab	Phase 2	Recruiting	2026-08	USA
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients NCT06934967 · Paroxysmal Nocturnal Hemoglobinuria (PNH) Drug: Iptacopan	Phase 3	Recruiting	2025-10	USA
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. NCT06858319 · Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases Drug: Zigakibart	Phase 3	Recruiting	2025-07	USA
Remibrutinib in Real-world Clinical Practice NCT07358364 · Chronic Spontaneous Urticaria	Observational	Recruiting	2026-02	USA
Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China NCT07476170 · ClinicalTrials.gov ↗ · HR+/HER2- Advanced or Metastatic Breast Cancer	Observational	Recruiting	2026-03	China
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease NCT07326709 · ClinicalTrials.gov ↗ · Huntington Disease Drug: Remibrutinib	Phase 3	Recruiting	2026-03	UK, USA, China
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. NCT05948943 · ClinicalTrials.gov ↗ · Lymphatic Malformations Drug: Alpelisib	Phase 2/3	Recruiting	2023-11	UK, USA
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC NCT07226986 · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy Drugs: Abiraterone, Enzalutamide	Phase 1/2	Recruiting	2025-12	USA
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis NCT06947993 · ClinicalTrials.gov ↗ · Atopic Dermatitis	Phase 2	Recruiting	2025-05	UK, USA, China
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD NCT06813911 · ClinicalTrials.gov ↗ · Atherosclerotic Cardiovascular Disease (ASCVD) Drugs: Inclisiran, Pelacarsen	Phase 3	Recruiting	2025-04	UK, USA, China
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy NCT07564401 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 1/2	Recruiting	2026-06	USA
A Study to Assess the Effects of Zigakibart on IgA Nephropathy. NCT07146906 · ClinicalTrials.gov ↗ · Immunoglobulin A Nephropathy (IgAN) Drug: Zigakibart	Phase 2	Recruiting	2026-03	USA, China
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab NCT07039422 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia Drug: Ianalumab	Phase 2	Recruiting	2026-06	UK, China
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer NCT05803941 · ClinicalTrials.gov ↗ · Prostate Cancer Drug: AAA617	Phase 4	Recruiting	2023-08	UK, USA
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia NCT06597006 · ClinicalTrials.gov ↗ · Familial Hypercholesterolemia - Homozygous Drug: Inclisiran	Phase 3	Recruiting	2025-02	UK, USA, China
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults NCT07249463 · ClinicalTrials.gov ↗ · Cryptosporidiosis	Phase 2	Recruiting	2025-12	USA
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation NCT07217067 · ClinicalTrials.gov ↗ · Atrial Fibrillation	Phase 2	Recruiting	2025-10	UK, USA, China
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma NCT05222529 · ClinicalTrials.gov ↗ · Asthma	Phase 2	Recruiting	2022-08	UK
CAR-T Long Term Follow Up (LTFU) Study NCT02445222 · ClinicalTrials.gov ↗ · Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program	Phase 3	Recruiting	2015-11	UK, USA, China
Home Reported Outcomes in PNH NCT06411626 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria	Observational	Recruiting	2024-06	USA
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) NCT07700056 · ClinicalTrials.gov ↗ · Chronic Pruritus of Unknown Origin Drug: Remibrutinib	Phase 3	Recruiting	2026-08	USA
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China NCT06931691 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria Drug: Iptacopan	Observational	Recruiting	2025-06	China
Asciminib Roll-over Study NCT04877522 · ClinicalTrials.gov ↗ · Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive Drugs: Asciminib single agent, Bosutinib, Dasatinib	Phase 4	Recruiting	2022-08	UK, USA, China
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) NCT06649110 · ClinicalTrials.gov ↗ · Healthy Volunteers, Pulmonary Arterial Hypertension	Phase 1/2	Recruiting	2024-10	UK, USA
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy NCT07498426 · ClinicalTrials.gov ↗ · Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)	Phase 3	Recruiting	2026-06	USA, China
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN NCT03955445 · ClinicalTrials.gov ↗ · C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis Drug: Iptacopan	Phase 3	Recruiting	2019-10	UK, USA, China
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia NCT06597019 · ClinicalTrials.gov ↗ · Familial Hypercholesterolemia - Heterozygous Drug: Inclisiran	Phase 3	Recruiting	2024-12	UK, USA, China
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN NCT06797518 · ClinicalTrials.gov ↗ · Glomerulonephritis, IGA, Immunoglobulin A Nephropathy Drug: Iptacopan	Phase 2	Recruiting	2025-02	USA
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation NCT07626281 · ClinicalTrials.gov ↗ · Inclisiran Formulation	Phase 1	Recruiting	2026-06	USA
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) NCT07681271 · ClinicalTrials.gov ↗ · Papulopustular Rosacea Drug: Remibrutinib	Phase 2	Recruiting	2026-07	USA, China
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy NCT07091019 · ClinicalTrials.gov ↗ · Chronic Myelogenous Leukemia - Chronic Phase	Observational	Recruiting	2025-12	USA
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments NCT07468071 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation Drugs: Cetuximab, Tislelizumab, TNO155	Phase 1/2	Recruiting	2026-06	China
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines NCT06868212 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria (CSU) Drugs: Dupilumab, Remibrutinib	Phase 3	Recruiting	2025-07	USA
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease NCT06824103 · ClinicalTrials.gov ↗ · Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease Drug: Ruxolitinib	Phase 4	Recruiting	2025-09	China
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy NCT06780670 · ClinicalTrials.gov ↗ · Prostate Cancer Drug: AAA817	Phase 2/3	Recruiting	2025-02	USA, China
Dabrafenib and/or Trametinib Rollover Study NCT03340506 · ClinicalTrials.gov ↗ · Melanoma, Non Small Cell Lung Cancer, Solid Tumor Drugs: Dabrafenib, Trametinib	Phase 4	Recruiting	2018-01	USA, China
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors NCT07660055 · ClinicalTrials.gov ↗ · Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer	Phase 1	Recruiting	2026-06	USA
DFT383 in Pediatric Participants With Nephropathic Cystinosis NCT06910813 · ClinicalTrials.gov ↗ · Nephropathic Cystinosis	Phase 1/2	Recruiting	2025-06	USA
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). NCT06751238 · ClinicalTrials.gov ↗ · Juvenile Psoriatic Arthritis Drug: Secukinumab	Phase 1	Recruiting	2025-09	USA
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan NCT07677267 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, Castration-Resistant	Observational	Recruiting	2026-06	USA
A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment NCT07786077 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia	Observational	Recruiting	2025-12	USA
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice NCT07779460 · ClinicalTrials.gov ↗ · Multiple Sclerosis	Observational	Recruiting	2026-04	USA
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis NCT07801495 · ClinicalTrials.gov ↗ · Moderate to Severe Psoriatic Arthritis Drug: DDY391	Phase 2	Recruiting	2026-10	USA
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer NCT07570979 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer (mCRPC) Drugs: Abiraterone, Enzalutamide	Phase 1	Recruiting	2026-05	USA
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) NCT07811869 · ClinicalTrials.gov ↗ · Chronic Pruritus of Unknown Origin Drug: Remibrutinib	Phase 3	Recruiting	2026-10	USA
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease NCT07737743 · ClinicalTrials.gov ↗ · Sjögren's Disease Drug: DDY391	Phase 2	Recruiting	2026-08	USA
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease NCT07235059 · ClinicalTrials.gov ↗ · Chronic Kidney Disease	Phase 1	Recruiting	2025-11	USA
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden NCT07621809 · ClinicalTrials.gov ↗ · Sjögren´s Disease Drug: Ianalumab	Phase 3	Recruiting	2026-07	USA
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. NCT06632600 · ClinicalTrials.gov ↗ · Chagas Disease	Phase 2	Recruiting	2025-04	USA
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. NCT07543120 · ClinicalTrials.gov ↗ · Hypertension (HTN) Drug: QCZ484	Phase 2	Recruiting	2026-05	USA
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy NCT07768371 · ClinicalTrials.gov ↗ · IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy Drug: Remibrutinib	Phase 3	Recruiting	2026-08	USA
Remibrutinib in Real-world Clinical Practice - a US Sub-study NCT07358780 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria	Observational	Recruiting	2026-02	USA
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer NCT07604571 · ClinicalTrials.gov ↗ · Advanced HR+/HER2- Breast Cancer Drugs: Fulvestrant, Letrozole	Phase 1	Recruiting	2026-05	USA
Home Reported Outcomes in C3G Study NCT07029542 · ClinicalTrials.gov ↗ · C3 Glomerulopathy	Observational	Recruiting	2025-04	USA

Showing the 100 most recently updated of 232 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Novartis Pharmaceuticals in the EU trials register (CTIS)

16 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with Novartis Pharmaceuticals as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease 2025-522227-99-00 · Nervous System Diseases Drug: Remibrutinib	Phase 3	Ongoing	Ireland + 19 more
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer 2025-522707-26-00 · Neoplasms	Phase 1	Authorised	Germany, France, Netherlands + 2 more
A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR) 2025-524496-23-00 · Skin and Connective Tissue Diseases Drug: Remibrutinib	Phase 2	Authorised	Bulgaria, Spain, France + 2 more
A clinical trial to learn about the effects of 225Ac-ETN029 in people with advanced solid tumors 2024-519111-34-00 · Neoplasms	Phase 1	Authorised	France, Spain, Italy + 1 more
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer 2025-524080-20-00 · Neoplasms	Phase 1	Authorised	France, Italy, Spain + 1 more
A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN) 2025-522824-29-00 · Immune system processes Drug: Atrasentan	Phase 3	Authorised	France, Spain
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP 2026-525974-21-00 · Cardiovascular Diseases	Phase 2	Authorised	Germany
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma. 2022-502365-26-00 · CTIS ↗ · Respiratory Tract Diseases	Phase 3	Ongoing	Poland, France, Slovakia + 4 more
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive 2025-523555-66-00 · CTIS ↗ · Neoplasms Drug: Ruxolitinib	Phase 3	Ongoing	Belgium, Germany, Austria + 6 more
A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC 2025-523276-23-00 · CTIS ↗ · Neoplasms Drugs: Bendamustine, Cyclophosphamide, Fludarabine	Phase 1	Authorised	Spain, France
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa 2025-523259-72-00 · CTIS ↗ · Immune System Diseases Drug: Remibrutinib	Phase 3	Authorised	Portugal, Greece, Germany + 9 more
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) 2025-522019-40-00 · CTIS ↗ · Neoplasms Drugs: Asciminib, Blinatumomab, Cytarabine	Phase 1	Authorised	Italy, Spain, Germany + 4 more
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors 2025-521911-38-00 · CTIS ↗ · Neoplasms Drugs: Fulvestrant, Goserelin, Letrozole	Phase 1	Ongoing	Italy, Germany, France + 3 more
A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer 2025-521000-22-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Spain, Italy, France
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors 2025-521702-18-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Germany, Portugal, France + 2 more
A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease 2025-520978-18-00 · CTIS ↗ · Female Urogenital Diseases and Pregnancy Complications	Phase 1	Authorised	Germany, Romania

Drugs in Novartis Pharmaceuticals trials

108 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 68 more in the trial list above.

Conditions in Novartis Pharmaceuticals trials

233 conditions

Breast Cancer6 Chronic Spontaneous Urticaria6 Immunoglobulin A Nephropathy5 Multiple Sclerosis5 Relapsing Multiple Sclerosis4 Systemic Lupus Erythematosus4 IgA Nephropathy4 Lupus Nephritis4 Hidradenitis Suppurativa4 Prostate Cancer4 Melanoma4 Sickle Cell Disease4 Carcinoma, Non-Small-Cell Lung4PIK3CA-related Overgrowth Spectrum (PROS)3Primary Immune Thrombocytopenia3Solid Tumor3 Generalized Myasthenia Gravis3 Primary Immune Thrombocytopenia (ITP)3Advanced HR+/HER2- Breast Cancer3Paroxysmal Nocturnal Hemoglobinuria3Spinal Muscular Atrophy (SMA)2Early Breast Cancer2Prostatic Neoplasms2Atypical Hemolytic Uremic Syndrome2

By trial register

Register	Trials	Recruiting
Clinical trials in USA	202	104
Clinical trials in China	110	49
Clinical trials in UK	98	40
Clinical trials in India	44	16
Clinical trials in Ireland	7	1
EU register (CTIS)	16	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about Novartis Pharmaceuticals trials

How many clinical trials does Novartis Pharmaceuticals sponsor?

Novartis Pharmaceuticals is the lead sponsor of 232 current trials on ClinicalTrials.gov in our USA, China, UK, India and Ireland registers, and 16 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Novartis Pharmaceuticals trials recruiting?

Yes. 120 of its 232 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Novartis Pharmaceuticals testing?

Its current trials name 108 drugs and biologicals as interventions. The most frequent are Remibrutinib (22), Ianalumab (16), Iptacopan (14), AAA617 (11) and Ribociclib (9). The number in brackets is how many of its trials name each drug.

Does Novartis Pharmaceuticals have clinical trials in Ireland?

Yes. 7 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Novartis Pharmaceuticals clinical trials